8VC

"Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery. Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitization and automation of chemical discovery and manufacturing."

"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."

"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."

"With the adoption of AI in creative tools, the amount of creative work is now growing by 30% a year. For example, last year, more photographs were generated than have ever been taken by human photographers. So, we’ve been asking ourselves ‘what infrastructure is going to be needed to manage this volume of work?’. One problem that doesn’t scale well is issue checking – there’s no Grammarly for creative work and to date this tedious work is still done by eye. Beyond issue checking, we believe AI provides creatives with insights akin to accessing a panel of experts. We see the role of AI as enabling people’s creative processes, not replacing them"

"We are extremely pleased with the progress to date, and this latest round of investment, from some of the leading names in business and technology, is an endorsement of our strategy and rapid growth."